Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Pharmaceuticals (Basel, Switzerland)|September 28, 2021
Progress in the Treatment of Migraine Attacks: From Traditional Approaches to EptinezumabDamiana Scuteri, Giacinto BagettaToxins|July 25, 2025
Translational Impact of Genetics and Epigenetics of CGRP System on Chronic Migraine Treatment with Onabotulinumtoxin A and Other Biotech DrugsDamiana Scuteri, Paolo MartellettiExpert Review of Neurotherapeutics|January 24, 2026
Positioning rimegepant in migraine prophylaxis: updated evidence and emerging perspectivesLanfranco Pellesi, Damiana Scuteri, Paolo MartellettiInternational Journal of Molecular Sciences|July 13, 2024
Basic, Translational, and Clinical Research on DementiaGiacinto Bagetta, Daniele Bano, Damiana ScuteriFrontiers in Behavioral Neuroscience|December 27, 2021
Aromatherapy in Stroke Patients: Is it Time to Begin?Marianna Contrada, Antonio Cerasa, Paolo Tonin, et al.Frontiers in Neurology|March 7, 2022
ROBOCOP (ROBOtic Care of Poststroke Pain): Study Protocol for a Randomized Trial to Assess Robot-Assisted Functional and Motor Recovery and Impact on Poststroke Pain DevelopmentLoris Pignolo, Paolo Tonin, Pierluigi Nicotera, et al.Expert Opinion on Emerging Drugs|June 14, 2026
Beyond Triptans in menstrual migraine: the emerging role of CGRP-Targeted therapiesLanfranco Pellesi, Damiana Scuteri, Andrea Burgalassi, et al.The Journal of Headache and Pain|July 31, 2021
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapyDamiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, et al.Current Neuropharmacology|May 16, 2017
Opioids Resistance in Chronic Pain ManagementLuigi A Morrone, Damiana Scuteri, Laura Rombolà, et al.Current Opinion in Pharmacology|October 11, 2021
New trends in pharmacological control of neuropsychiatric symptoms of dementiaDamiana Scuteri, Maria Tiziana Corasaniti, Paolo Tonin, et al.Pageof 7